# OnCo record cullinan-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/cullinan-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "cullinan-therapeutics" ;
  schema:name "Cullinan Therapeutics"@en ;
  schema:description "Cullinan develops T-cell engager antibodies, which pull a patient's T cells onto target cells, for both cancer and autoimmune disease. Its cancer lead, CLN-049, targets FLT3 on acute myeloid leukaemia cells and is entering a potentially registrational trial."@en ;
  schema:url <https://onco.cc/companies/cullinan-therapeutics/>, <https://cullinantherapeutics.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://cullinantherapeutics.com/>, <https://www.sec.gov/Archives/edgar/data/1789972/000119312526336700/cgem-ex99_1.htm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/aml/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/flt3/>, <https://onco.cc/targets/cd3/>, <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/bcma/> ;
  onco:trials <https://onco.cc/trials/nct04036682/> .